Monopar Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Monopar Therapeutics, Inc. on June 27, 2019. The report details the results of the Company's 2019 annual meeting of stockholders held on the same date. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results rather than financial performance.
Material Changes
No material financial changes were reported in this filing. The primary event was the successful ratification of the Board of Directors and the independent auditor.
Guidance, Outlook, and Voting Results
Management commentary and future guidance are not included in this filing. The following voting outcomes were reported:
- Shareholder Participation: Of 9,291,420.614 shares entitled to vote, 7,381,339.6 shares were represented at the meeting.
- Proposal 1 (Election of Directors): Six directors were elected unanimously. All 7,381,339.6 votes cast were "For" each nominee, with zero votes "Against," "Withheld," or "Abstained."
- Proposal 2 (Ratification of Auditor): Stockholders ratified the selection of BPM LLP as the independent registered public accounting firm for the year ending December 31, 2019. The vote was unanimous with 7,381,339.6 votes "For" and zero votes otherwise.
Investor Verification Checklist
- Verify the full list of elected directors and their tenure terms in the Company's Schedule 14C Information Statement.
- Confirm the engagement letter and scope of work with BPM LLP for the 2019 fiscal year.
- Review the Company's most recent 10-K or 10-Q filings for actual financial performance metrics, as this 8-K contains no financial data.